REMI
Price
$0.06
Change
-$0.00 (-0.00%)
Updated
Dec 18 closing price
SAFLF
Price
$0.98
Change
+$0.09 (+10.11%)
Updated
Dec 16 closing price
Ad is loading...

REMI vs SAFLF

Header iconREMI vs SAFLF Comparison
Open Charts REMI vs SAFLFBanner chart's image
Remedent
Price$0.06
Change-$0.00 (-0.00%)
Volume$1K
CapitalizationN/A
Safilo Group Spa
Price$0.98
Change+$0.09 (+10.11%)
Volume$100
CapitalizationN/A
REMI vs SAFLF Comparison Chart
Loading...
REMI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAFLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REMI vs. SAFLF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REMI is a Hold and SAFLF is a Buy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (REMI: $0.05 vs. SAFLF: $0.98)
Brand notoriety: REMI and SAFLF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: REMI: 69% vs. SAFLF: 23%
Market capitalization -- REMI: $3.4M vs. SAFLF: $529.04M
REMI [@Medical Specialties] is valued at $3.4M. SAFLF’s [@Medical Specialties] market capitalization is $529.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REMI’s FA Score shows that 0 FA rating(s) are green whileSAFLF’s FA Score has 0 green FA rating(s).

  • REMI’s FA Score: 0 green, 5 red.
  • SAFLF’s FA Score: 0 green, 5 red.
According to our system of comparison, REMI is a better buy in the long-term than SAFLF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REMI’s TA Score shows that 2 TA indicator(s) are bullish while SAFLF’s TA Score has 4 bullish TA indicator(s).

  • REMI’s TA Score: 2 bullish, 0 bearish.
  • SAFLF’s TA Score: 4 bullish, 0 bearish.
According to our system of comparison, SAFLF is a better buy in the short-term than REMI.

Price Growth

REMI (@Medical Specialties) experienced а 0.00% price change this week, while SAFLF (@Medical Specialties) price change was +9.84% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.17%. For the same industry, the average monthly price growth was +1.60%, and the average quarterly price growth was -0.66%.

Reported Earning Dates

REMI is expected to report earnings on Nov 27, 2024.

Industries' Descriptions

@Medical Specialties (-4.17% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAFLF($529M) has a higher market cap than REMI($3.4M). SAFLF YTD gains are higher at: 6.973 vs. REMI (-43.299). SAFLF has higher annual earnings (EBITDA): 127M vs. REMI (-192.98K). SAFLF has more cash in the bank: 78.7M vs. REMI (83.3K). REMI has less debt than SAFLF: REMI (5.46K) vs SAFLF (184M). SAFLF has higher revenues than REMI: SAFLF (1.03B) vs REMI (1.13M).
REMISAFLFREMI / SAFLF
Capitalization3.4M529M1%
EBITDA-192.98K127M-0%
Gain YTD-43.2996.973-621%
P/E RatioN/A9.07-
Revenue1.13M1.03B0%
Total Cash83.3K78.7M0%
Total Debt5.46K184M0%
FUNDAMENTALS RATINGS
REMI vs SAFLF: Fundamental Ratings
REMI
SAFLF
OUTLOOK RATING
1..100
4029
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9189
PRICE GROWTH RATING
1..100
7863
P/E GROWTH RATING
1..100
4662
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REMI's Valuation (46) in the null industry is somewhat better than the same rating for SAFLF (89). This means that REMI’s stock grew somewhat faster than SAFLF’s over the last 12 months.

REMI's Profit vs Risk Rating (100) in the null industry is in the same range as SAFLF (100). This means that REMI’s stock grew similarly to SAFLF’s over the last 12 months.

SAFLF's SMR Rating (89) in the null industry is in the same range as REMI (91). This means that SAFLF’s stock grew similarly to REMI’s over the last 12 months.

SAFLF's Price Growth Rating (63) in the null industry is in the same range as REMI (78). This means that SAFLF’s stock grew similarly to REMI’s over the last 12 months.

REMI's P/E Growth Rating (46) in the null industry is in the same range as SAFLF (62). This means that REMI’s stock grew similarly to SAFLF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REMISAFLF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
25%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
41%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
58%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
32%
Bullish Trend 2 days ago
28%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
28%
Bearish Trend 2 days ago
26%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
REMI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAFLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HLPPY3.93-0.04
-1.13%
Hang Lung Properties Ltd.
ISNPY24.42-0.42
-1.67%
Intesa Sanpaolo S.p.A.
KUBTY59.68-1.44
-2.36%
Kubota Corp.
BUDZ0.03N/A
-4.46%
WEED, Inc.
CYDY0.12-0.01
-9.70%
CytoDyn Inc.

REMI and

Correlation & Price change

A.I.dvisor tells us that REMI and AHICF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that REMI and AHICF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REMI
1D Price
Change %
REMI100%
+10.00%
AHICF - REMI
23%
Poorly correlated
N/A
SNANF - REMI
20%
Poorly correlated
N/A
SAFLY - REMI
7%
Poorly correlated
N/A
RDGL - REMI
3%
Poorly correlated
-3.33%
SAFLF - REMI
2%
Poorly correlated
N/A
More

SAFLF and

Correlation & Price change

A.I.dvisor tells us that SAFLF and GMED have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SAFLF and GMED's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAFLF
1D Price
Change %
SAFLF100%
N/A
GMED - SAFLF
28%
Poorly correlated
-1.97%
MYGN - SAFLF
24%
Poorly correlated
-4.12%
JMPHF - SAFLF
23%
Poorly correlated
N/A
OFIX - SAFLF
22%
Poorly correlated
-2.23%
MROPF - SAFLF
21%
Poorly correlated
N/A
More